CIK 0001847367 · <br>Emerging growth company
ALUMIS INC.
Sign in to watch- Ticker
- ALMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 650-231-6625
- Business address
- 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- FL2021-001, Inc.
- Open-market buys, last 90 days
- $10,726,255
- in 1 filing
- Open-market sales, last 90 days
- $1,037,650
- in 7 filings
Net +$9,688,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- AKKARAJU SRINIVAS +$9.7M Director sold 4% of stake
- Schroer John R. −$5K Chief Financial Officer sold 3% of stake
- Hardiman Roy C. −$4K Chief Business & Strategy Ofcr sold <1% of stake
- Goldstein David M −$4K Chief Scientific Officer sold 2% of stake
- Bradley Mark Christopher −$4K Chief Development Officer sold 1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-29 | Schroer John R. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +111,950 | 111,950 | ||
| 2025-07-29 | Hardiman Roy C. Chief Business & Strategy Ofcr | Grant or award | +28,000 | 206,401 | ||
| 2025-07-29 | Hardiman Roy C. Chief Business & Strategy Ofcr | Grant or award · Stock Option (Right to Buy) | +111,950 | 111,950 | ||
| 2025-07-29 | Goldstein David M Chief Scientific Officer | Grant or award | +27,000 | 29,115 | ||
| 2025-07-29 | Goldstein David M Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +107,950 | 107,950 | ||
| 2025-07-29 | Drappa Jorn Chief Medical Officer | Grant or award | +25,450 | 28,450 | ||
| 2025-07-29 | Drappa Jorn Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +101,850 | 101,850 | ||
| 2025-07-29 | Bradley Mark Christopher Chief Development Officer | Grant or award | +26,750 | 48,728 | ||
| 2025-07-29 | Bradley Mark Christopher Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +107,100 | 107,100 | ||
| 2025-07-29 | Babler Martin President, CEO and Chairman | Grant or award · Stock Option (Right to Buy) | +662,000 | 662,000 | ||
| 2025-07-29 | Babler Martin President, CEO and Chairman | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2025-07-10 | Pangali Sanam Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-05-21 | AKKARAJU SRINIVAS Director | Grant or award | +1,214,582 | 4,801,370 | ||
| 2025-05-21 | Machado Patrick Director | Grant or award | +7,064 | 7,064 | ||
| 2025-05-21 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +44,364 | 44,364 | ||
| 2025-05-21 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +11,189 | 11,189 | ||
| 2025-05-21 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +41,499 | 41,499 | ||
| 2025-05-21 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +13,804 | 13,804 | ||
| 2025-05-21 | Machado Patrick Director | Grant or award · Stock Option (Right to Buy) | +19,528 | 19,528 | ||
| 2025-05-21 | AyurMaya Capital Management Company, LP Director | Grant or award | +4,493,741 | 15,139,707 |
Page 6 of 21 · 405 trades